#AAD26: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposurenews2026-03-28T16:00:08+00:00March 28th, 2026|Endpoints News|
Otsuka buys Transcend Therapeutics for $700M upfrontnews2026-03-27T18:21:02+00:00March 27th, 2026|Endpoints News|
FDA approves Rocket’s gene therapy for ultra-rare immune diseasenews2026-03-27T15:13:30+00:00March 27th, 2026|Endpoints News|
AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trialnews2026-03-27T12:00:35+00:00March 27th, 2026|Endpoints News|
Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidatenews2026-03-27T11:21:39+00:00March 27th, 2026|Endpoints News|
AstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected populationnews2026-03-27T10:46:08+00:00March 27th, 2026|Endpoints News|
FDA gives Denali accelerated approval for rare disease drugnews2026-03-25T19:24:58+00:00March 25th, 2026|Endpoints News|
How Seaport is hedging against failure in Phase 2b depression studynews2026-03-25T18:00:28+00:00March 25th, 2026|Endpoints News|
After tumultuous year, Sarepta plots rebound with early data on RNA therapiesnews2026-03-25T15:41:06+00:00March 25th, 2026|Endpoints News|
